Pharmaceutical Formulation Company in India

A pharmaceutical formulation company turns a known molecule into a stable, manufacturable finished product and the documentation to file it — preformulation, formulation development, analytical and stability studies, scale-up, technology transfer and the regulatory dossier. Molkem Labs runs all of this as one programme, from molecule to market, and coordinates GMP manufacturing through a vetted CMO network.

We are development-focused and asset-light: Molkem Labs leads and manages formulation science, analytical methodology, and dossier development, and coordinates commercial manufacturing through vetted Contract Manufacturing Organisation (CMO) partners rather than an owned plant. This provides scientific accountability and a credible path to commercial supply without implying that Molkem owns the manufacturing facility.

Our pharmaceutical formulation development services span preformulation, formulation development, analytical method development and validation, stability studies, scale-up and exhibit batches, technology transfer and CTD/eCTD dossier preparation. Buyers comparing drug formulation companies or drug formulation services usually need most of this chain, so we scope it as one accountable programme or as individual services.

Oral solids (tablets and capsules, immediate- to extended-release), oral liquids (solutions, suspensions and syrups), sterile parenteral solutions, and semi-solids and topicals (creams, gels and ointments). We're honest about scope up front, so you never find a capability gap mid-project.

Yes — our preformulation and formulation team designs for solubility, bioavailability and stability, and we assess developability early so you know what a difficult (e.g. poorly soluble) molecule will need before the programme commits.

Every engagement starts under a signed NDA. Your molecule, your data and your formulation know-how stay your property, and data is kept segregated across the programme, including the manufacturing partner network. IP ownership is written into the agreement before any material or data changes hands.

We build development data and dossiers for CDSCO (India), US FDA, EMA, ANVISA, Health Canada, TGA, NMPA, and Rest of World (ROW) markets, following ICH guidelines. The target market is agreed at the feasibility stage because it shapes the studies, documentation, and batches required.

It depends on the molecule, the dosage form, the target market and how much of the programme you outsource — there's no flat price list. We provide a written scope, a realistic timeline and a stage-wise cost, so you decide with the number in front of you.